GlassScriptPhysician profile
Joanna H Queen
NPI 1508125089
$4,510.33
in general payments reported to CMS, 2019-2025
28 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $203 · 2021: $361 · 2022: $562 · 2023: $1,474 · 2024: $1,045 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,978.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $793.99 | 2022-2024 | |
| Alcon Vision LLC | $691.02 | 2019-2025 | Hydrus Microstent, Rocklatan, Clareon |
| Sun Pharmaceutical Industries INC. | $522.14 | 2019-2025 | Cequa |
| Glaukos Corporation | $408.72 | 2021-2025 | Idosetr |
| New World Medical,INC. | $228.78 | 2023-2024 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Ocular Therapeutix, INC. | $176.64 | 2019-2025 | Dextenza |
| Ivantis, INC | $171.88 | 2021 | |
| Aerie Pharmaceuticals, INC. | $165.90 | 2019-2020 | |
| Sight Sciences, INC. | $157.50 | 2024 | Omni Surgical System |
| Novartis Pharmaceuticals Corporation | $154.73 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $154.73 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $141.42 | 2024 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $140.21 | 2023 | Syfovre |
| Bausch & Lomb Americas INC. | $127.23 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Takeda Pharmaceuticals U.S.A., INC. | $79.99 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60.22 | 2024 | Tepezza |
| Dompe US, INC. | $57.65 | 2024-2025 | Oxervate |
| Allergan, INC. | $43.02 | 2021-2022 | |
| Horizon Therapeutics Plc | $40.23 | 2021-2023 | Tepezza |
| Oyster Point Pharma, INC. | $39.09 | 2022-2023 | Tyrvaya |
| Ucb, INC. | $31.45 | 2025 | |
| Shire North American Group INC | $23.21 | 2019 | |
| Kala Pharmaceuticals, INC. | $20.36 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.84 | 2020 | |
| Merz North America, INC. | $17.29 | 2019 | |
| Eyepoint US, INC. | $16.65 | 2019 | |
| Biotissue Holdings INC. | $14.81 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $13.63 | 2024 | Tecnis Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Queen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.